Logo image of NMR

NOMURA HOLDINGS INC-SPON ADR (NMR) Stock Fundamental Analysis

NYSE:NMR - New York Stock Exchange, Inc. - US65535H2085 - ADR - Currency: USD

6.79  +0.04 (+0.59%)

After market: 6.79 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to NMR. NMR was compared to 235 industry peers in the Capital Markets industry. Both the profitability and financial health of NMR have multiple concerns. NMR has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

NMR had positive earnings in the past year.
In the past year NMR has reported a negative cash flow from operations.
Each year in the past 5 years NMR has been profitable.
In multiple years NMR reported negative operating cash flow during the last 5 years.
NMR Yearly Net Income VS EBIT VS OCF VS FCFNMR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500B -500B 1T -1T -1.5T

1.2 Ratios

NMR has a Return On Assets of 0.60%. This is in the lower half of the industry: NMR underperforms 68.94% of its industry peers.
The Return On Equity of NMR (9.82%) is comparable to the rest of the industry.
NMR has a Return On Invested Capital of 0.62%. This is in the lower half of the industry: NMR underperforms 71.49% of its industry peers.
NMR had an Average Return On Invested Capital over the past 3 years of 0.41%. This is significantly below the industry average of 7.84%.
The last Return On Invested Capital (0.62%) for NMR is above the 3 year average (0.41%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 0.6%
ROE 9.82%
ROIC 0.62%
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.41%
ROIC(5y)0.41%
NMR Yearly ROA, ROE, ROICNMR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2 -2 4 6 8

1.3 Margins

NMR has a worse Profit Margin (7.19%) than 65.11% of its industry peers.
NMR's Profit Margin has declined in the last couple of years.
The Operating Margin of NMR (9.96%) is worse than 70.21% of its industry peers.
In the last couple of years the Operating Margin of NMR has declined.
With a Gross Margin value of 39.95%, NMR is not doing good in the industry: 65.11% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of NMR has declined.
Industry RankSector Rank
OM 9.96%
PM (TTM) 7.19%
GM 39.95%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
NMR Yearly Profit, Operating, Gross MarginsNMR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

1

2. Health

2.1 Basic Checks

NMR has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, NMR has less shares outstanding
NMR has a better debt/assets ratio than last year.
NMR Yearly Shares OutstandingNMR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B
NMR Yearly Total Debt VS Total AssetsNMR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10T 20T 30T 40T 50T

2.2 Solvency

NMR has an Altman-Z score of -0.25. This is a bad value and indicates that NMR is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.25, NMR is doing worse than 79.57% of the companies in the same industry.
NMR has a Debt/Equity ratio of 10.44. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of NMR (10.44) is worse than 89.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 10.44
Debt/FCF N/A
Altman-Z -0.25
ROIC/WACCN/A
WACCN/A
NMR Yearly LT Debt VS Equity VS FCFNMR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5T 10T

2.3 Liquidity

A Current Ratio of 0.23 indicates that NMR may have some problems paying its short term obligations.
With a Current ratio value of 0.23, NMR is not doing good in the industry: 88.09% of the companies in the same industry are doing better.
A Quick Ratio of 0.23 indicates that NMR may have some problems paying its short term obligations.
NMR has a Quick ratio of 0.23. This is amonst the worse of the industry: NMR underperforms 88.09% of its industry peers.
Industry RankSector Rank
Current Ratio 0.23
Quick Ratio 0.23
NMR Yearly Current Assets VS Current LiabilitesNMR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5T 10T 15T 20T 25T

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 96.52% over the past year.
The Earnings Per Share has been growing by 10.96% on average over the past years. This is quite good.
The Revenue has grown by 13.94% in the past year. This is quite good.
NMR shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 19.39% yearly.
EPS 1Y (TTM)96.52%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%13.06%
Revenue 1Y (TTM)13.94%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%6.19%

3.2 Future

NMR is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -4.35% yearly.
The Revenue is expected to decrease by -8.82% on average over the next years.
EPS Next Y-4.32%
EPS Next 2Y-4.35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-3.69%
Revenue Next 2Y-1.64%
Revenue Next 3Y-8.82%
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
NMR Yearly Revenue VS EstimatesNMR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 1T 2T 3T 4T
NMR Yearly EPS VS EstimatesNMR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 50 100

5

4. Valuation

4.1 Price/Earnings Ratio

NMR is valuated reasonably with a Price/Earnings ratio of 8.49.
82.13% of the companies in the same industry are more expensive than NMR, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of NMR to the average of the S&P500 Index (28.04), we can say NMR is valued rather cheaply.
Based on the Price/Forward Earnings ratio of 8.83, the valuation of NMR can be described as reasonable.
NMR's Price/Forward Earnings ratio is rather cheap when compared to the industry. NMR is cheaper than 83.83% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 37.64, NMR is valued rather cheaply.
Industry RankSector Rank
PE 8.49
Fwd PE 8.83
NMR Price Earnings VS Forward Price EarningsNMR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, NMR is valued a bit cheaper than 71.49% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 22.29
NMR Per share dataNMR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

NMR's earnings are expected to decrease with -4.35% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)0.77
EPS Next 2Y-4.35%
EPS Next 3YN/A

6

5. Dividend

5.1 Amount

NMR has a Yearly Dividend Yield of 4.61%, which is a nice return.
Compared to an average industry Dividend Yield of 8.04, NMR has a dividend in line with its industry peers.
NMR's Dividend Yield is rather good when compared to the S&P500 average which is at 2.35.
Industry RankSector Rank
Dividend Yield 4.61%

5.2 History

The dividend of NMR is nicely growing with an annual growth rate of 15.59%!
NMR has paid a dividend for at least 10 years, which is a reliable track record.
The dividend of NMR decreased in the last 3 years.
Dividend Growth(5Y)15.59%
Div Incr Years2
Div Non Decr Years2
NMR Yearly Dividends per shareNMR Yearly Dividends per shareYearly Dividends per share 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

5.3 Sustainability

NMR pays out 33.03% of its income as dividend. This is a sustainable payout ratio.
DP33.03%
EPS Next 2Y-4.35%
EPS Next 3YN/A
NMR Yearly Income VS Free CF VS DividendNMR Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500B -500B -1T -1.5T
NMR Dividend Payout.NMR Dividend Payout, showing the Payout Ratio.NMR Dividend Payout.PayoutRetained Earnings

NOMURA HOLDINGS INC-SPON ADR

NYSE:NMR (7/25/2025, 7:00:00 PM)

After market: 6.79 0 (0%)

6.79

+0.04 (+0.59%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)04-25 2025-04-25/dmh
Earnings (Next)07-29 2025-07-29
Inst Owners38.49%
Inst Owner Change-0.15%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap20.22B
Analysts69.23
Price Target6.96 (2.5%)
Short Float %0.05%
Short Ratio2.65
Dividend
Industry RankSector Rank
Dividend Yield 4.61%
Yearly Dividend0.26
Dividend Growth(5Y)15.59%
DP33.03%
Div Incr Years2
Div Non Decr Years2
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)23.99%
Min EPS beat(2)-10.21%
Max EPS beat(2)58.19%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.83%
PT rev (3m)-7%
EPS NQ rev (1m)0.01%
EPS NQ rev (3m)-65.23%
EPS NY rev (1m)0.01%
EPS NY rev (3m)-0.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.2%
Valuation
Industry RankSector Rank
PE 8.49
Fwd PE 8.83
P/S 0.63
P/FCF N/A
P/OCF N/A
P/B 0.85
P/tB 0.85
EV/EBITDA 22.29
EPS(TTM)0.8
EY11.78%
EPS(NY)0.77
Fwd EY11.33%
FCF(TTM)-3.55
FCFYN/A
OCF(TTM)-1.56
OCFYN/A
SpS10.86
BVpS7.96
TBVpS7.96
PEG (NY)N/A
PEG (5Y)0.77
Profitability
Industry RankSector Rank
ROA 0.6%
ROE 9.82%
ROCE 1.58%
ROIC 0.62%
ROICexc 0.68%
ROICexgc 0.69%
OM 9.96%
PM (TTM) 7.19%
GM 39.95%
FCFM N/A
ROA(3y)0.36%
ROA(5y)0.36%
ROE(3y)5.9%
ROE(5y)5.66%
ROIC(3y)0.41%
ROIC(5y)0.41%
ROICexc(3y)0.45%
ROICexc(5y)0.45%
ROICexgc(3y)0.46%
ROICexgc(5y)0.46%
ROCE(3y)1.07%
ROCE(5y)1.07%
ROICexcg growth 3Y16.49%
ROICexcg growth 5Y7.83%
ROICexc growth 3Y15.92%
ROICexc growth 5Y7.53%
OM growth 3Y-11.17%
OM growth 5Y-4.76%
PM growth 3Y-7.1%
PM growth 5Y-8.33%
GM growth 3Y-22.42%
GM growth 5Y-9.54%
F-Score6
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 10.44
Debt/FCF N/A
Debt/EBITDA 67.92
Cap/Depr 1410.99%
Cap/Sales 18.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.23
Quick Ratio 0.23
Altman-Z -0.25
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)988.49%
Cap/Depr(5y)668.06%
Cap/Sales(3y)14.69%
Cap/Sales(5y)11.69%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.52%
EPS 3Y34.65%
EPS 5Y10.96%
EPS Q2Q%13.06%
EPS Next Y-4.32%
EPS Next 2Y-4.35%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)13.94%
Revenue growth 3Y43.77%
Revenue growth 5Y19.39%
Sales Q2Q%6.19%
Revenue Next Year-3.69%
Revenue Next 2Y-1.64%
Revenue Next 3Y-8.82%
Revenue Next 5YN/A
EBIT growth 1Y72.34%
EBIT growth 3Y27.7%
EBIT growth 5Y13.71%
EBIT Next Year20164.7%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-122.5%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-883.38%
OCF growth 3YN/A
OCF growth 5YN/A